首页> 外文期刊>American journal of therapeutics >Avascular Osteonecrosis of the Mandible Following Bisphosphonate Therapy
【24h】

Avascular Osteonecrosis of the Mandible Following Bisphosphonate Therapy

机译:双膦酸盐治疗后下颌骨的无血管性骨坏死

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer patients receiving bisphosphonate therapy, both intravenously and orally, are predisposed to developing osteonecrosis of the jaw. We present a case of a 66-year-old man with metastatic prostate cancer who spontaneously developed avascular necrosis of the mandible after being on intravenous zoledronic acid for 1 year. Jaw osteonecrosis commonly presents with mild to severe jaw pain. Although most of the reported cases give a history of dental procedures, there have been cases of osteonecrosis developing spontaneously. In cases of established osteonecrosis of the jaw, there is little evidence to suggest that the discontinuation of bisphosphonate therapy aides in healing, as bisphosphonates have a very long half-life in the bone tissue. Treatment measures include evaluation by dental and oncological services, consideration for antibiotic therapy, and mainly a minimally to nonsurgical approach. In the absence of a definitive cure, the emphasis rests greatly on prevention.
机译:接受双膦酸盐治疗的癌症患者,无论是静脉内还是口服,都容易发生颌骨坏死。我们介绍了一个患有转移性前列腺癌的66岁男性,该患者在接受唑来膦酸静脉注射1年后自发形成下颌骨的血管坏死。下颌骨坏死通常表现为轻度至重度下颌疼痛。尽管大多数报道的病例都有牙科手术史,但仍有骨坏死病例自发发展。在确定颌骨坏死的情况下,几乎没有证据表明中止双膦酸盐治疗有助于愈合,因为双膦酸盐在骨组织中的半衰期非常长。治疗措施包括通过牙科和肿瘤科进行评估,考虑使用抗生素治疗,以及主要采用最低限度的非手术方法。在没有确定的治疗方法的情况下,重点放在预防上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号